Blackstone Commits $1.5 Billion to Fund Pfizer Obesity Drug Development
Blackstone has committed $1.5 billion to fund the development of Pfizer’s obesity drug candidate, berobenatide, as part of a strategic effort to share R&D…

Blackstone Life Sciences has committed up to $1.5 billion to support the clinical development of berobenatide, an obesity drug candidate currently in Pfizer’s pipeline. This capital injection is structured to offset research and development costs associated with advancing the candidate through late-stage clinical trials.
This transaction reflects a broader trend of private equity firms assuming the financial risk of high-cost pharmaceutical development in exchange for future royalty streams or milestone payments. By offloading a portion of the R&D expenditure, Pfizer preserves its balance sheet liquidity while maintaining exposure to the high-growth GLP-1 market.
Blackstone Life Sciences
The obesity drug sector remains a primary focus for major pharmaceutical firms due to significant projected market demand. Securing external funding for specific assets allows companies to diversify their clinical portfolios without over-leveraging internal resources.
Market participants should monitor the progress of berobenatide through upcoming regulatory milestones. The success of this drug candidate is critical for Pfizer to remain competitive against established incumbents in the weight-loss therapeutic space.
Future developments will likely hinge on the efficacy and safety data generated during the funded trials. Any delays or negative clinical outcomes would impact the valuation of the asset and the financial returns expected by the investment group.
More stories
- The Week in Games: GTA 6 turns attention into cash
- US data centres emit 25.7m tonnes of CO2, Harvard says
- German founders need 3,942 hours to open small business
- Leaked Deutsche Bank files test Sewing's reform narrative
- UAE employers plan 2.8% pay rises for 2027
- Bessent urges Nvidia to seek outside CEO as scrutiny grows
- CapitaLand, Neon target China's $2.8 trillion experience economy
- Listed firms in Indonesia face fire scrutiny as 2.88m hectares burned
- Nasdaq falls 0.15% as chipmakers extend losses
- Workday widens AI controls with C1.ai deal and Claude link
Latest news
- Social Security raises 2027 benefits 3.6%
- Hull City 2–0 Brighton: When Resilience Beat Reputation
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence

